Europa Biosite is delighted to announce the partnership of Europa Biosite and Micronbrane Medical to distribute their mNGS technologies across Europe.
The landscape of infectious diseases in Europe has become increasingly challenging, due to rising concerns regarding antimicrobial resistance (AMR), the emergence of novel pathogens and the re-emergence of communicable diseases with the need for advanced diagnostic and surveillance methods becoming critical.
Micronbrane Medical are a pioneering force in Metagenomic Next-Generation Sequencing (mNGS). This partnership enhances the capabilities of European researchers and clinical laboratories in combating infectious diseases through the adoption of Micronbrane Medical’s innovative mNGS assay.
Dr. Mengchu Wu, CEO, co-founder, and chairwoman of Micronbrane Medical said: “Our strategic emphasis is to systematically remove the barriers to ubiquitous mNGS use to improve human health. Our assay, Pathogen Real-Time Identification by sequencing, or PaRTI-Seq™, delivers cost-effective, comprehensive results in less than 24 hours, facilitating more comprehensive research, accurate diagnostics and tracking of all kinds of infectious diseases.”
Martijn Blommaart, Director of Supplier Development of Europa Biosite said: “Micronbrane Medical shares our values of quality, innovation, and service. We are pleased to support our customers in research and clinical laboratories in transitioning to mNGS with Micronbrane Medical’s innovative and cost-effective products.”
If you are interested in developing a partnership with any of the Europa Biosite subsidiaries, please do get in touch.
Partner with Europa Biosite
Europa Biosite partners with life science suppliers who share our values on quality, innovation and service.
If you are looking for a leading European distributor partner, we want to hear from you.